GALT — Galectin Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $159.96m
- $275.98m
Annual cashflow statement for Galectin Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -30.5 | -38.8 | -41.1 | -47 | -30.8 |
| Non-Cash Items | 2.47 | 2.75 | 3.42 | 3 | 6.35 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.75 | 4.97 | 4.68 | 2.28 | 0.609 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -24.3 | -31.1 | -33 | -41.8 | -23.9 |
| Other Investing Cash Flow Items | 0 | 0 | 0 | 0 | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | 0 | 0 | 0 | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 36.8 | 10 | 40 | 31.2 | 26.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 12.5 | -21.1 | 7.07 | -10.5 | 2.6 |